CO2020001981A2 - Proteínas que se unen a nkg2d, cd16 y flt3 - Google Patents
Proteínas que se unen a nkg2d, cd16 y flt3Info
- Publication number
- CO2020001981A2 CO2020001981A2 CONC2020/0001981A CO2020001981A CO2020001981A2 CO 2020001981 A2 CO2020001981 A2 CO 2020001981A2 CO 2020001981 A CO2020001981 A CO 2020001981A CO 2020001981 A2 CO2020001981 A2 CO 2020001981A2
- Authority
- CO
- Colombia
- Prior art keywords
- flt3
- bind
- nkg2d
- proteins
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
Se describen proteínas de unión multiespecífica que se unen al receptor de NKG2D, CD16 y a un antígeno asociado a tumores FLT3, así como composiciones farmacéuticas y métodos terapéuticos útiles para el tratamiento del cáncer.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762539421P | 2017-07-31 | 2017-07-31 | |
PCT/US2018/044610 WO2019028027A1 (en) | 2017-07-31 | 2018-07-31 | PROTEINS BINDING TO NKG2D, CD16 AND FLT3 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020001981A2 true CO2020001981A2 (es) | 2020-05-29 |
Family
ID=65233032
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0001981A CO2020001981A2 (es) | 2017-07-31 | 2020-02-25 | Proteínas que se unen a nkg2d, cd16 y flt3 |
Country Status (15)
Country | Link |
---|---|
US (1) | US20200165344A1 (es) |
EP (1) | EP3661554A4 (es) |
JP (2) | JP2020529410A (es) |
KR (1) | KR20200033302A (es) |
CN (1) | CN111132698A (es) |
AU (1) | AU2018309712A1 (es) |
BR (1) | BR112020001972A2 (es) |
CA (1) | CA3070986A1 (es) |
CO (1) | CO2020001981A2 (es) |
EA (1) | EA202090387A1 (es) |
IL (1) | IL272374A (es) |
MA (1) | MA49769A (es) |
MX (1) | MX2020001257A (es) |
SG (1) | SG11202000632QA (es) |
WO (1) | WO2019028027A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
CA3054079A1 (en) | 2017-02-20 | 2018-08-23 | Dragonfly Therapeutics, Inc. | Proteins binding her2, nkg2d and cd16 |
PE20220278A1 (es) | 2018-02-08 | 2022-02-25 | Dragonfly Therapeutics Inc | Dominios variables de anticuerpos que se dirigen al receptor nkg2d |
MX2022004430A (es) * | 2019-10-15 | 2022-07-19 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), al cumulo de diferenciacion 16 (cd16) y a la tirosina cinasa 3 similar a fms (flt3). |
CN117580865A (zh) * | 2021-06-29 | 2024-02-20 | 山东先声生物制药有限公司 | Cd16抗体及其应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2222706T5 (pl) * | 2007-12-14 | 2017-09-29 | Novo Nordisk As | Przeciwciała przeciwko ludzkiemu NKG2D i ich zastosowania |
AR071891A1 (es) * | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
UY32808A (es) * | 2009-07-29 | 2011-02-28 | Abbott Lab | Inmunoglobulinas como dominio variable dual y usos de las mismas |
BR112012015740B1 (pt) * | 2009-12-23 | 2020-09-29 | Synimmune Gmbh | Anticorpo anti-flt3, seu uso,bem como composição compreendendo o referido anticorpo e molécula de ácido nucleico |
UY33492A (es) * | 2010-07-09 | 2012-01-31 | Abbott Lab | Inmunoglobulinas con dominio variable dual y usos de las mismas |
LT2794658T (lt) * | 2011-12-19 | 2017-05-10 | Synimmune Gmbh | Bispecifinė antikūno molekulė |
JP6628966B2 (ja) * | 2012-06-14 | 2020-01-15 | 中外製薬株式会社 | 改変されたFc領域を含む抗原結合分子 |
US20170022291A1 (en) * | 2014-04-01 | 2017-01-26 | Adimab, Llc | Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use |
WO2016166139A1 (en) * | 2015-04-14 | 2016-10-20 | Eberhard Karls Universität Tübingen | Bispecific fusion proteins for enhancing immune responses of lymphocytes against tumor cells |
-
2018
- 2018-07-31 US US16/635,079 patent/US20200165344A1/en active Pending
- 2018-07-31 MA MA049769A patent/MA49769A/fr unknown
- 2018-07-31 EA EA202090387A patent/EA202090387A1/ru unknown
- 2018-07-31 WO PCT/US2018/044610 patent/WO2019028027A1/en active Application Filing
- 2018-07-31 EP EP18840650.8A patent/EP3661554A4/en active Pending
- 2018-07-31 MX MX2020001257A patent/MX2020001257A/es unknown
- 2018-07-31 SG SG11202000632QA patent/SG11202000632QA/en unknown
- 2018-07-31 BR BR112020001972-0A patent/BR112020001972A2/pt unknown
- 2018-07-31 KR KR1020207005238A patent/KR20200033302A/ko not_active Application Discontinuation
- 2018-07-31 AU AU2018309712A patent/AU2018309712A1/en active Pending
- 2018-07-31 CA CA3070986A patent/CA3070986A1/en active Pending
- 2018-07-31 JP JP2020505208A patent/JP2020529410A/ja active Pending
- 2018-07-31 CN CN201880062880.1A patent/CN111132698A/zh active Pending
-
2020
- 2020-01-30 IL IL272374A patent/IL272374A/en unknown
- 2020-02-25 CO CONC2020/0001981A patent/CO2020001981A2/es unknown
-
2023
- 2023-05-01 JP JP2023075458A patent/JP2023106433A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
BR112020001972A2 (pt) | 2020-08-04 |
JP2020529410A (ja) | 2020-10-08 |
KR20200033302A (ko) | 2020-03-27 |
MA49769A (fr) | 2021-04-21 |
EA202090387A1 (ru) | 2020-05-21 |
SG11202000632QA (en) | 2020-02-27 |
US20200165344A1 (en) | 2020-05-28 |
CA3070986A1 (en) | 2019-02-07 |
AU2018309712A1 (en) | 2020-02-13 |
JP2023106433A (ja) | 2023-08-01 |
CN111132698A (zh) | 2020-05-08 |
IL272374A (en) | 2020-03-31 |
EP3661554A4 (en) | 2021-04-21 |
WO2019028027A1 (en) | 2019-02-07 |
EP3661554A1 (en) | 2020-06-10 |
MX2020001257A (es) | 2020-08-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2020001981A2 (es) | Proteínas que se unen a nkg2d, cd16 y flt3 | |
CO2020016619A2 (es) | Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso | |
CL2018001152A1 (es) | Composiciones y métodos para el tratamiento del cáncer | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
EA201990293A1 (ru) | Мультиспецифичные антитела против cd40 и cd137 | |
MX2019009468A (es) | Proteínas de unión multiespecíficas para la activación de células asesinas naturales y usos terapéuticos de las mismas para tratar cáncer. | |
MX2021002970A (es) | Proteinas de union a nkg2d, cd16 y un antigeno asociado a tumor. | |
MX2020006668A (es) | Anticuerpos para lilrb2. | |
SV2017005355A (es) | Composiciones de portador-anticuerpo y métodos para realizarlas y utilizarlas | |
PE20210167A1 (es) | Proteinas de union multiespecificas y mejoras con estas | |
CO2022015929A2 (es) | Proteínas que se unen a nkg2d, cd16 y clec12a | |
CO2022004757A2 (es) | Proteínas que se unen a nkg2d, cd16 y flt3 | |
ECSP17011657A (es) | Conjugados de fármacos con anticuerpos anti-cdh6 | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
MX2019009848A (es) | Proteínas que se unen a her2, nkg2d y cd16. | |
MX2019009566A (es) | Proteinas de union a bcma, nkg2d y cd16. | |
PH12017500406A1 (en) | Novel anti-mfi2 antibodies and methods of use | |
CL2023002108A1 (es) | Proteínas unión multiespecíficas se unen a cd33, nkg2d, cd16, métodos de uso. | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
EA201791249A1 (ru) | Получаемые из cd44v6 циклические пептиды для лечения злокачественных опухолей и связанных с ангиогенезом заболеваний | |
CO2021001410A2 (es) | Proteínas de unión multiespecíficas que se unen a bcma, nkg2d y cd16 y métodos de uso | |
MX2019009541A (es) | Proteinas que se unen a psma, nkg2d y cd16. | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
MX2019009847A (es) | Proteínas que se unen a cd123, nkg2d y cd16. | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. |